senrex, Bavi as a "dud" is not a realistic description of it in light of current knowledge about it and about the now-burgeoning field of aminopholipid biochemistry. The "dud" part of Bavi, if there is one, is in current and past choices of clinical application. However, I cannot imagine for a moment that those scientists involved in this aminopholipid sector are going to come up empty-handed, and PPHM has an enormous lead in the sector. One problem is that the salutary and relatively side-effect free anti-inflammatory and anti-tumor effects observed ad nauseam (and financed by us stockholders) in pre-clinical testing must be investigated in humans in relatively short time-frames driven mostly by economic considerations rather than realistic therapeutic treatment durations. Simply-put, I would be willing to bet even more investment dollars that Bavi, or similar, will be a life-extender to almost all biological forms subject to inflammation and tumor formation if taken(for instance) as a daily nasal spray (since it has been established to easily enter the bloodstream after passing through the nasal mucosa). How do we measure life extension and generalized improvement in "well-being" in a reasonable period of time? Killing advanced lung cancers, as we have seen in multiple I-O failures lately, is not a reasonable expectation. As mentioned several times here, the "spin-offs" from trials of one purpose are often more valuable than the stated goal and end-point of the trial, so those of us here involved the clinical arena are keeping our fingers crossed that the post-hoc findings of the Bavi PIII trial (autopsy review of various organs systems and Bavi-specific staining of accumulation in various organs, infection sites AND tumor) will be productive. We are fortunate, as a small biotech, to have in our grasp such a wealth of human material to study after treatment with one of our lead products. We are also obligated to all patients and stockholders to make the most of this opportunity. The biggest hurdle has been overcome, presumably, and that is SAFETY. Pharma is full of agents that kill tumors, but kill patients too. Now the search is on for the correct application of potentially a myriad antiphospholipid MABs. Let's give some credit where it is due.
